Navigation Links
Searching for therapeutic synergy in primary effusion lymphoma
Date:5/1/2013

Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies. In this issue of the Journal of Clinical Investigation, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat multiple myeloma and cutaneous T cell lymphoma, respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors. These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. MP3 song-searching can increase risk for drivers
2. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
3. Novel gene-searching software improves accuracy in disease studies
4. GW professor researching ways to improve human tissue dissection, reduce blood transfusions
5. Targeted therapeutics for colon cancer to be presented at AACR meeting
6. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
7. 5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
8. FORMA Therapeutics teams with TGen Drug Development
9. Device implanted in brain has therapeutic potential for Huntingtons disease
10. Enzyme offers new therapeutic target for cancer drugs
11. Lauren Sciences LLCs research team at Ben-Gurion University awarded Campbell Foundation grant to develop a V-Smart therapeutic for neuro-HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... has launched online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to ... of a seafood-rich diet. These resources have been developed for use by ...
(Date:1/22/2017)... MALO, FRANCE (PRWEB) , ... January 22, 2017 , ... ... Indian Ocean, isolated from the rest of the world with ZANZIBAR MILKY CREAM. Inspired ... Phytocéane used key ingredients like Virgin Coconut Oil and moisturizing vegetal coral to create ...
(Date:1/21/2017)... ... 21, 2017 , ... Caronlab Australia, an Australian company known for health and ... Hilton Head, SC, where it benefited from outstanding meetings with major retail buyers. , ... wellness products. At this trade show, the company had the chance to demonstrate its ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you ... from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty ... ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower ...
(Date:1/21/2017)... ... 2017 , ... In the United States, 20 million women and 10 million ... often feel shame for having struggled with an eating disorder as well as common ... Strong in Life After an Eating Disorder” -- to be featured at this year’s ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... global  anxiety disorders and depression treatment market  is expected to reach a value ... anticipated to drive the market growth in the coming years. Increasing adoption of ... recent years. Continue Reading ... ... ...
(Date:1/23/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, ... collaboration agreement with the Children,s Hospital of Philadelphia ... a US key opinion leader in the mitochondrial medicine field. ... ... NeuroVive,s research program, NVP015, in certain experimental disease models. The ...
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 ... "US Clinical Laboratory Testing Market By Type of Test (Tumor, ... Independent), & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS ... ... an attractive destination for healthcare services, market segments, especially clinical ...
Breaking Medicine Technology: